Veronika Seebacher - Gynecology

Author Information

Veronika Seebacher is affiliated with the Department for Gynecology and Gynecologic Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Centre, Medical University of Vienna, located at Waehringer Guertel 18-20, 1090, Vienna, Austria. Her work primarily focuses on various aspects of gynecologic oncology, including the prognostic factors and treatment outcomes of gynecological malignancies.

Research Contributions

Veronika Seebacher has made significant contributions to the field of gynecologic oncology, with a particular focus on identifying prognostic markers and assessing the impact of different treatments on patient outcomes. Her research includes studies on the expression of Prostate-Specific Membrane Antigen (PSMA) in ovarian cancer, the false negative rate of 18F-FDG PET/CT in cervical cancer, and the impact of nutritional risk factors and sarcopenia on survival in patients with recurrent gynecological malignancies. Additionally, she has explored the prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer and the role of frailty in the management of elderly gynecological cancer patients.

Aliases

V Seebacher, V. Seebacher, Veronika Seebacher

Publication and Citation Metrics

Metric	Value
Citation Count	1099
h-index	18
Paper Count	53

Publications:

Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer

DOI: 10.3390/jpm12040551

Year: 2022

1018 False negative rate at 18F-FDG PET/CT inpara-aortic lymphnode involvement inpatients with locally advanced cervicalcancer: impact of PET technology

DOI: 10.1136/ijgc-2021-esgo.87

Year: 2021

The impact of nutritional risk factors and sarcopenia on survival in patients treated with pelvic exenteration for recurrent gynaecological malignancy: a retrospective cohort study

DOI: 10.1007/s00404-021-06273-7

Year: 2021

False negative rate at 18F-FDG PET/CT in para-aortic lymphnode involvement in patients with locally advanced cervical cancer: impact of PET technology

DOI: 10.1186/s12885-021-07821-9

Year: 2021

The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).

DOI: 10.1016/j.urolonc.2020.02.002

Year: 2020

Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real‐World Precision Cancer Medicine Platform

DOI: 10.1634/theoncologist.2019-0904

Year: 2020

The clinical value of the urokinase-plasminogen activator system (uPA) in patients with radical cystectomy (RC) for bladder cancer

DOI: 10.1016/s2666-1683(20)33620-x

Year: 2020

Impact of frailty on the management of patients with gynecological cancer aged 80 years and older

DOI: 10.1007/s00404-020-05807-9

Year: 2020

Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis.

DOI: 10.1016/j.clgc.2019.11.007

Year: 2019

Prognostic value of serum creatine level in patients with vulvar cancer

DOI: 10.1038/s41598-019-47560-3

Year: 2019

How does salt intake affect menstrual health?

How do dyes aid in cancer detection?

What Should You Do During the First Stage?

What is MRI?

What Role Do Continuing Education and Certifications Play?

What Should I Look for When Choosing a Plan?

What is Tolerance in Gynecology?

What are the Long-Term Outcomes?

What is Congenital Rubella Syndrome?

What Treatments are Available in Fetal Medicine?

Partnered Content Networks

Relevant Topics